Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

Gewen Tan; Hideki Kasuya; Tevfik Tolga Sahin; Kazuo Yamamura; Zhiwen Wu; Yusuke Koide; Yoshihiro Hotta; Toshio Shikano; Suguru Yamada; Akiyuki Kanzaki; Tsutomu Fujii; Hiroyuki Sugimoto; Shuji Nomoto; Yoko Nishikawa; Maki Tanaka; Naoko Tsurumaru; Toshie Kuwahara; Saori Fukuda; Toru Ichinose; Toyone Kikumori; Shin Takeda; Akimasa Nakao; Yasuhiro Kodera

doi:10.1002/ijc.29163

Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

Gewen Tan, Hideki Kasuya^*, Tevfik Tolga Sahin, Kazuo Yamamura, Zhiwen Wu, Yusuke Koide, Yoshihiro Hotta, Toshio Shikano, Suguru Yamada, Akiyuki Kanzaki, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Yoko Nishikawa, Maki Tanaka, Naoko Tsurumaru, Toshie Kuwahara, Saori Fukuda, Toru Ichinose, Toyone KikumoriShin Takeda, Akimasa Nakao, Yasuhiro Kodera

^*Corresponding author for this work

Department of Surgery & Science

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.

Original language	English
Pages (from-to)	1718-1730
Number of pages	13
Journal	International Journal of Cancer
Volume	136
Issue number	7
DOIs	https://doi.org/10.1002/ijc.29163
State	Published - 2015/04/01

Keywords

Angiogenesis inhibitor
Bevacizumab
HSV
Oncolytic herpes virus HF10

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/ijc.29163

Cite this

Tan, G., Kasuya, H., Sahin, T. T., Yamamura, K., Wu, Z., Koide, Y., Hotta, Y., Shikano, T., Yamada, S., Kanzaki, A., Fujii, T., Sugimoto, H., Nomoto, S., Nishikawa, Y., Tanaka, M., Tsurumaru, N., Kuwahara, T., Fukuda, S., Ichinose, T., ... Kodera, Y. (2015). Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. International Journal of Cancer, 136(7), 1718-1730. https://doi.org/10.1002/ijc.29163

@article{f2f2c6206cff44bb9d4ee44fe62c1d5b,

title = "Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft",

abstract = "Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.",

keywords = "Angiogenesis inhibitor, Bevacizumab, HSV, Oncolytic herpes virus HF10",

author = "Gewen Tan and Hideki Kasuya and Sahin, {Tevfik Tolga} and Kazuo Yamamura and Zhiwen Wu and Yusuke Koide and Yoshihiro Hotta and Toshio Shikano and Suguru Yamada and Akiyuki Kanzaki and Tsutomu Fujii and Hiroyuki Sugimoto and Shuji Nomoto and Yoko Nishikawa and Maki Tanaka and Naoko Tsurumaru and Toshie Kuwahara and Saori Fukuda and Toru Ichinose and Toyone Kikumori and Shin Takeda and Akimasa Nakao and Yasuhiro Kodera",

note = "Publisher Copyright: {\textcopyright} 2014 UICC.",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/ijc.29163",

language = "英語",

volume = "136",

pages = "1718--1730",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

Tan, G, Kasuya, H, Sahin, TT, Yamamura, K, Wu, Z, Koide, Y, Hotta, Y, Shikano, T, Yamada, S, Kanzaki, A, Fujii, T, Sugimoto, H, Nomoto, S, Nishikawa, Y, Tanaka, M, Tsurumaru, N, Kuwahara, T, Fukuda, S, Ichinose, T, Kikumori, T, Takeda, S, Nakao, A & Kodera, Y 2015, 'Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft', International Journal of Cancer, vol. 136, no. 7, pp. 1718-1730. https://doi.org/10.1002/ijc.29163

TY - JOUR

T1 - Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

AU - Tan, Gewen

AU - Kasuya, Hideki

AU - Sahin, Tevfik Tolga

AU - Yamamura, Kazuo

AU - Wu, Zhiwen

AU - Koide, Yusuke

AU - Hotta, Yoshihiro

AU - Shikano, Toshio

AU - Yamada, Suguru

AU - Kanzaki, Akiyuki

AU - Fujii, Tsutomu

AU - Sugimoto, Hiroyuki

AU - Nomoto, Shuji

AU - Nishikawa, Yoko

AU - Tanaka, Maki

AU - Tsurumaru, Naoko

AU - Kuwahara, Toshie

AU - Fukuda, Saori

AU - Ichinose, Toru

AU - Kikumori, Toyone

AU - Takeda, Shin

AU - Nakao, Akimasa

AU - Kodera, Yasuhiro

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.

AB - Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.

KW - Angiogenesis inhibitor

KW - Bevacizumab

KW - HSV

KW - Oncolytic herpes virus HF10

UR - http://www.scopus.com/inward/record.url?scp=84920903880&partnerID=8YFLogxK

U2 - 10.1002/ijc.29163

DO - 10.1002/ijc.29163

M3 - 学術論文

C2 - 25156870

AN - SCOPUS:84920903880

SN - 0020-7136

VL - 136

SP - 1718

EP - 1730

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 7

ER -

Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this